All In Biotech

Drug Trial Radar · NCT03757559

A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users

A Single-dose, Nested-randomized, Double-blind, Double-dummy, Placebo- and Active-controlled Crossover Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users

Last checked: Nov 20, 2026Latest source record: Jul 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 226 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

226

Actual

Start

Apr 15, 2013

Primary completion

Mar 8, 2014

Study completion Mar 8, 2014

Sponsor

Lead sponsor
Tris Pharma, Inc.Industry
Sponsor type
Industry
First posted
Nov 29, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study was to evaluate the abuse potential of single doses of cebranopadol (GRT6005) relative to hydromorphone (immediate-release formulation \[IR\] and placebo in 48 non-dependent recreational opioid users. Secondary objectives were to evaluate the abuse potential of hydromorphone IR compared to placebo (trial validation), to evaluate the safety and tolerability of single doses of cebranopadol (200, 400, and 800 micrograms), and to evaluate pharmacokinetics (PK) of cebranopadol and optionally some of its metabolites.

Conditions

  • Abuse, Drug

Interventions

  • Cebranopadol 100 microgramsDrug

    Tablets were taken under fasted conditions with non-carbonated water.

  • Cebranopadol 400 microgramsDrug

    Tablets were taken under fasted conditions with non-carbonated water.

  • Hydromorphone hydrochloride 4 milligramsDrug

    Over-encapsulated immediate-release tablets were taken under fasted conditions with non-carbonated water.

  • Placebo matching hydromorphoneDrug

    Placebo matching over-encapsulated hydromorphone tablets were taken under fasted conditions with non-carbonated water.

  • Placebo matching cebranopadolDrug

    Placebo matching cebranopadol tablets were taken under fasted conditions with non-carbonated water.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Drug Liking (at this moment)Time frame: At 16 distinct time points between 30 minutes and 56 hours after drug intake

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • INC Research

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.